News

Tapping into PD-1/PD-L1 immune checkpoint proteins — which serve as a kind of natural off switch for an overactive immune response — might help keep myasthenia gravis (MG) under control. That’s according to the findings of a new study from China using immune cells from patients, which suggested that…

Rituximab may be safe and effective in treating women with myasthenia gravis (MG) that’s driven by antibodies that target muscle-specific tyrosine kinase (MuSK), an analysis of patients at a single center in China shows. Significant symptom relief was seen by 90% of patients after a month of treatment and it…

Nine-time tennis Grand Slam champion Monica Seles, who has myasthenia gravis (MG), is teaming up with pharmaceutical company Argenx on a campaign aimed at raising awareness — and increasing understanding — of the rare neuromuscular disease. “I am excited to partner with the Argenx team — to inspire…

Ultomiris (ravulizumab-cwvz) is now closer to being covered by public Canadian healthcare systems when used to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — one of its approved indications in the country. That’s according to its developer…

Certain inflammatory molecules known as cytokines may play a role in a person’s risk of developing myasthenia gravis (MG), according to a recent genetic study. The research suggests some of these immune-system signaling molecules could increase the risk of the autoimmune disease, while others might offer protection. The findings, which…

Two genes that help to control the human body’s biological clock are dysregulated in myasthenia gravis (MG) — a disease marked by symptoms that often grow worse throughout the day — according to the findings of a new study from China. Study data indicated that dysregulation of these genes,…

People with generalized myasthenia gravis (gMG) can carry certain types of self-reactive antibodies — proteins that mistakenly target the body’s own cells and tissues — that drive the disease but are treatment resistant, according to a new study by Yale School of Medicine researchers. These self-reactive antibodies, or autoantibodies,…

Treatment with gefurulimab, an experimental self-administered injection therapy, outperformed a placebo in easing symptoms of generalized myasthenia gravis (gMG) among people with the chronic autoimmune disease, the results of a Phase 3 clinical trial show. The trial met both its primary and secondary endpoints, or goals, with treatment…

A case report from Germany showed that two women with severe, treatment-resistant myasthenia gravis (MG) responded well to blinatumomab, suggesting the anti-cancer medication may offer a new option for hard-to-treat autoimmune diseases. “Since this first-in-human experience comprises two cases, our findings should be viewed as proof-of-concept rather than evidence…

Surgery to remove the thymus gland led to a long-term reduction in levels of immune T-cells and to temporary changes in levels of proteins involved in regulating immune and inflammatory responses in people with myasthenia gravis (MG), a study shows. There were no significant effects on the levels of…